Sarasota, FL, Oct. 12, 2017 (GLOBE NEWSWIRE) — Zion Market Research has published a new report titled “Human Insulin Market by Product (Drug and Drug Delivery Devices) for Type 1 Diabetes, Type 2 Diabetes Application -Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”. According to the report, the global Human Insulin Market accounted for USD 27.00 billion in 2015 and is expected to reach USD 43.6 billion by 2021, growing at a CAGR of around 8.3% between 2016 and 2021.
The global human insulin market is expected to witness significant growth during the forecast period. This growth is attributed due to increasing the risk of diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. An insulin regimen is often required in the treatment of gestational diabetes and diabetes-associated with certain conditions or syndromes (e.g.pancreatic diseases, drug- or chemical-induced diabetes, endocrinopathies, insulin-receptor disorders, certain genetic syndromes). In all instances of insulin use, the insulin dosage must be individualized and balanced with medical nutrition therapy and exercise.
Browse through 13 Market Tables and 25 Figures spread through 110 Pages and in-depth TOC on “Human Insulin Market by Product (Drug and Drug Delivery Devices) for Type 1 Diabetes, Type 2 Diabetes Application and Forecast 2015 – 2021”.
Request Free Sample copy of Global Human Insulin Market Report @ https://www.zionmarketresearch.com/sample/human-insulin-market
Drugs segment dominated the human insulin market across the globe in 2015 followed by drug delivery device due to its excess demand, rising proportion of the aging population in developed countries, growing research & development for drug discovery & development, increasing market accessibility of generic products worldwide, and rising government initiatives.
In terms of drugs, biosimilars drugs were expected to account for the largest market share of the human insulin market in the upcoming forecast period. Demand for biosimilar drugs is strong in both developed and developing countries due to its low-cost therapy. This is driven by the need for the best valuable treatment, which can often be expensive. Biosimilar insulin drug may offer a less-costly alternative to existing human insulin biologics.
Browse the full “Human Insulin Market by Product (Drug and Drug Delivery Devices) for Type 1 Diabetes, Type 2 Diabetes Application – Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021” report at https://www.zionmarketresearch.com/report/human-insulin-market
On the basis of drug delivery device, the pens segment is expected to account for the largest market share in 2015 followed by syringe and Pen Needle. This growth can be endorsed due to growing market focus of pen manufacturers on emerging countries such as China, India, and Brazil. Insulin pens look similar to oversized ink pens, making them a potentially convenient and discreet way of carrying insulin which makes him one of the demanding factors over the other market.
Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/human-insulin-market
Key market players of human insulin market include Eli Lilly, GlaxoSmithKline, Biocon, Sanofi-Aventis, Julphar, Novo Nordisk, SemBioSys, Ypsomed AG and Wockhardt.
Request customized copy of report @ https://www.zionmarketresearch.com/custom/101
This report segments the global human insulin market as follows:
Human Insulin Market: Product Segment Analysis
- Insulin Analogs and Biosimilars
- Human Insulin Biologics
- Drug Delivery Devices
- Pen Needles
Human Insulin Market: Application Segment Analysis
- Insulin-dependent diabetes mellitus (Type 1)
- Non-Insulin dependent diabetes mellitus (Type 2)
Human Insulin Market: Regional Segment Analysis
- North America
- Asia Pacific
- Latin America
- The Middle East & Africa
- Home Infusion Therapy Market: https://www.zionmarketresearch.com/report/home-infusion-therapy-market
- Telemedicine Market: https://www.zionmarketresearch.com/report/telemedicine-market
- Medical Education Market: https://www.zionmarketresearch.com/report/medical-education-market
- Advanced Wound Care Management Market: https://www.zionmarketresearch.com/report/global-advanced-wound-care-management-market
- Biomaterials Market: https://www.zionmarketresearch.com/report/biomaterials-market
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research
CONTACT: Contact Us: Joel John 4283, Express Lane, Suite 634-143, Sarasota, Florida 34249, United States Tel: +49-322 210 92714 USA/Canada Toll-Free No.1-855-465-4651 Email: [email protected]rketresearch.com Website: https://www.zionmarketresearch.com
Latest posts by Nasdaq NewsFeed (see all)
- PinnacleART Makes the 2018 Inc. 5000 List of America’s Fastest-Growing Private Companies - August 16, 2018
- Transforming lives and businesses through digital innovation - August 16, 2018
- Indberetning af ledende medarbejderes og disses nærtståendes transaktioner med aktier i Totalbanken A/S - August 16, 2018